Free tool
FAERS Monitor: Cycloset
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020866 or its brand name (Cycloset, Bromocriptine Mesylate). Reports on generic versions are filed under their own applications.
Reports
646
Serious
513
79% of reports
Hospitalization
234
Death reported
30
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea46
- drug ineffective37
- headache35
- vomiting33
- dizziness31
- pyrexia29
- fatigue28
- drug exposure during pregnancy25
- neuroleptic malignant syndrome24
- tremor22
- somnolence20
- diarrhoea19
- dyspnoea19
- blood creatine phosphokinase increased18
- hypotension18
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 32 |
| 2005 | 30 |
| 2006 | 34 |
| 2007 | 33 |
| 2008 | 37 |
| 2009 | 15 |
| 2010 | 19 |
| 2011 | 78 |
| 2012 | 62 |
| 2013 | 16 |
| 2014 | 16 |
| 2015 | 30 |
| 2016 | 29 |
| 2017 | 30 |
| 2018 | 23 |
| 2019 | 21 |
| 2020 | 8 |
| 2021 | 16 |
| 2022 | 22 |
| 2023 | 27 |
| 2024 | 45 |
| 2025 | 14 |
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,513 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neuroleptic malignant syndromeSignal | 24 | 66.0 | 44.6 | 1,470 |
| drug exposure during pregnancySignal | 25 | 24.0 | 16.3 | 528 |
| blood creatine phosphokinase increasedSignal | 18 | 20.4 | 12.9 | 313 |
| tremorSignal | 22 | 4.3 | 2.9 | 53 |
| somnolenceSignal | 20 | 3.2 | 2.1 | 29 |
| hypotensionSignal | 18 | 2.9 | 1.9 | 21 |
| pyrexiaSignal | 29 | 2.7 | 1.9 | 31 |
| vomitingSignal | 33 | 2.3 | 1.6 | 23 |
| dizzinessSignal | 31 | 2.0 | 1.4 | 15 |
| nausea | 46 | 1.9 | 1.4 | 19 |
| headache | 35 | 1.8 | 1.3 | 12 |
| fatigue | 28 | 1.2 | 0.8 | 1 |
| dyspnoea | 19 | 1.1 | 0.7 | 0 |
| diarrhoea | 19 | 1.0 | 0.6 | 0 |
| drug ineffective | 37 | 0.9 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.